DOX-based chemoembolization is a key therapy for intermediate HCC, but its utility is limited by preexisting and acquired tumor resistance, as we proved that DOX itself also enhanced drug resistance by upregulating the expression of ABC transporters. Here, ABCG2 is linked to hepatocellular carcinoma.